α5IA
CAS: 215874-86-5
Ref. 3D-QIA87486
1mg | Descontinuado | ||
2mg | Descontinuado | ||
5mg | Descontinuado | ||
10mg | Descontinuado | ||
25mg | Descontinuado | ||
50mg | Descontinuado | ||
100mg | Descontinuado | ||
250mg | Descontinuado | ||
500mg | Descontinuado |
Informação sobre produto
Alpha5IA is a benzodiazepine-binding compound that inhibits the activity of the gamma-aminobutyric acid type A receptor. It has been shown to inhibit neuronal death in mouse hippocampal cells and is being developed as a potential treatment for Alzheimer's disease. Alpha5IA has also been shown to have clinical efficacy in humans, with minimal side effects. This drug is nonselective, meaning that it is active at all GABA receptors, but it does not cross the blood-brain barrier. Alpha5IA has been used in clinical pharmacology studies to evaluate its efficacy and safety profile in humans, and has shown promising results.